Head-to-head · Cost-Efficiency Index
9amHealth vs Kova
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
9amHealth
Cost-first shoppers who want gLP-1 prescribing folded into a broader diabetes/metabolic-health membership with labs and specialist access, if you're willing to enroll to see the price.
Visit 9amHealthKova
Cost-first shoppers who want not applicable to consumers -- this is an infrastructure vendor for other healthcare businesses, not a patient-facing GLP-1 provider.
Visit KovaThe verdict
9amHealth and Kova tie on the Cost-Efficiency Index at 44/100, so neither wins outright on the numbers. For most shoppers we'd start with 9amHealth (ranked #471, a hair above #477) — Cost-first shoppers who want gLP-1 prescribing folded into a broader diabetes/metabolic-health membership with labs and specialist access, if you're willing to enroll to see the price. But Kova is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs 9amHealth.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | 9amHealth | Kova |
|---|---|---|
| Cost-Efficiency Index | 44/100 | 44/100 |
| Semaglutide / mo | Not disclosed | Not disclosed |
| Tirzepatide / mo | Not disclosed | Not disclosed |
| Semaglutide / yr (modeled) | — | — |
| Tirzepatide / yr (modeled) | — | — |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #471 | #477 |
9amHealth
44/100Where the value is
- Confirmed genuine direct-to-individual GLP-1 weight-loss prescribing (Wegovy, Zepbound), not just diabetes management
- Publishes its own outcomes data rather than only marketing copy: 17.6% weight loss with GLP-1s vs 9.3% without over 12 months
- Named clinical team (Dr. Reilly, Dr. Goodwin, Dr. Mansour, Dr. Waring) plus pharmacists and a dietitian on staff
The tradeoffs
- No membership or medication price is published anywhere on the accessible public pages, and both a /pricing and a /weight-loss URL 404'd
- States served are not listed on any accessible page
Kova
44/100Where the value is
- Displays LegitScript, HIPAA-compliance, and 'SecureMetrics Verified' badges at the platform level
The tradeoffs
- Not a consumer-facing prescriber -- no patient intake, cart, or pricing exists on the site
- No GLP-1 price, medical director, pharmacy partner, or state list to report
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.